CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...